Short Interest in Caladrius Biosciences Inc (NASDAQ:CLBS) Grows By 10.3%

Caladrius Biosciences Inc (NASDAQ:CLBS) was the target of a significant increase in short interest in June. As of June 30th, there was short interest totalling 41,600 shares, an increase of 10.3% from the May 30th total of 37,700 shares. Based on an average trading volume of 42,500 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.5% of the company’s stock are sold short.

Shares of NASDAQ:CLBS opened at $2.94 on Tuesday. Caladrius Biosciences has a 52-week low of $2.16 and a 52-week high of $6.83. The business has a 50-day moving average price of $2.68.

Caladrius Biosciences (NASDAQ:CLBS) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.05). As a group, research analysts anticipate that Caladrius Biosciences will post -1.66 EPS for the current year.



A hedge fund recently bought a new stake in Caladrius Biosciences stock. Wesbanco Bank Inc. purchased a new stake in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $36,000. Wesbanco Bank Inc. owned approximately 0.10% of Caladrius Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 7.59% of the company’s stock.

Several equities research analysts have weighed in on the company. Chardan Capital reissued a “buy” rating and issued a $6.00 price target on shares of Caladrius Biosciences in a report on Sunday, May 12th. ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Zacks Investment Research raised Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a report on Monday, July 8th. Finally, WBB Securities assumed coverage on Caladrius Biosciences in a report on Tuesday, May 14th. They issued a “speculative buy” rating and a $6.75 price target for the company. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $9.25.

About Caladrius Biosciences

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Recommended Story: Stock Portfolio Tracker

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.